Viridian financings to repay Hercules debt and fund TED franchise and pipeline development

 

Viridian Therapeutics launches concurrent note and equity offerings to repay Hercules debt and fund TED franchise and pipeline development

• $150 million convertible senior notes due 2032 offered in concurrent underwritten financing transaction.
• $100 million of common and Series B non-voting convertible preferred stock offered concurrently.
• Positive pivotal Phase 3 REVEAL-1 and REVEAL-2 data support elegrobart in thyroid eye disease, with BLA filing targeted in 2027.
• First-quarter 2026 results highlight launch readiness ahead of veligrotug's June 30 FDA PDUFA date.
• Q1 2026 non-GAAP EPS was -$0.90, down 3% YoY, and revenue $141,000, up 96% YoY, both beating estimates.
• SEC filing shows wider Q1 2026 net loss of $104.9M compared with the prior-year period.

https://finviz.com/quote?t=VRDN&p=d